First in Class Telomerase Inhibitor (Imetelstat) for Lower-Risk Myelodysplastic Syndromes (LR-MDS)

home / case-based-peer-perspectives / first-in-class-telomerase-inhibitor-imetelstat-for-lower-risk-myelodysplastic-syndromes-lr-mds

Dr. Mikkael Skeres, MD, shares his thoughts and experience with Imetelstat, a first in class telomerase inhibitor for use in patients with lower-risk Myelodysplastic syndromes.